Fraiman, et al, original RCT data revealed greater risks of SAE outweighing clinical benefit since no reductions in hospitalization and death in the trials program. This means that if properly evaluated in fall 2020, PFE/BNT should have never been EUA approved or gone on market.
- Forums
- Breaking News
- COVID AND THE VACCINE - TRUTH, LIES, AND MISCONCEPTIONS REVEALED
COVID AND THE VACCINE - TRUTH, LIES, AND MISCONCEPTIONS REVEALED, page-56451
-
- There are more pages in this discussion • 42,581 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online